Intrexon through collaboration is utilizing its synthetic biology platform for the potential treatment and prevention of graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT), which significantly impairs the quality of life and survival of many recipients. To address the underlying pathologies of GvHD, engineered cell platforms may be utilized to express and deliver interleukin-2 (IL-2), a cytokine critical for modulation of the immune system. Approaches may include infusion of regulatory T cells (Tregs) conditionally expressing IL-2 utilizing Intrexon’s proprietary gene control approaches such as its RheoSwitch® platform
and deployment of orally-delivered microbe-based ActoBiotics® therapeutics
expressing IL-2 targeting delivery to the digestive tract, a site which plays a significant role in the body’s immune system. These new ways of treating and preventing GvHD have the potential to broaden the number of patients eligible to receive allogeneic HCST and also increase the number of effective donor/recipient combinations.